Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ibio Inc's Business Segments
Ibio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Collaborative Revenues
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Collaborative Revenues0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaborative Revenues | $ 0 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Collaborative Revenues0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaborative Revenues | $ 0 | - |
Description of Ibio Inc
Ibio Inc. is a biotechnology company that focuses on developing and commercializing plant-based pharmaceuticals and vaccines. The company was founded in 2008 and is headquartered in Bryan, Texas.
The core technology of Ibio is its proprietary plant-based expression system, known as the iBioLaunch platform. This platform allows for the rapid and cost-effective production of high-quality proteins, antibodies, and other biologics in plants. By using plants as bioreactors, Ibio is able to bypass many of the limitations and challenges associated with traditional manufacturing methods.
One of the key advantages of the iBioLaunch platform is its scalability. Ibio can quickly scale up production to meet demand, making it an attractive solution for the production of vaccines and other critical medical supplies, especially during times of crisis such as pandemics. This flexibility has positioned Ibio as a leading player in the biotherapeutics market.
In addition to its core platform, Ibio also offers a range of services to support the development and manufacturing of biologics. These services include cell line development, upstream and downstream process development, and analytical testing services. These services enable Ibio to provide end-to-end solutions for its clients, from early-stage development through to commercial manufacturing.
Ibio has a diverse portfolio of collaborations and partnerships with pharmaceutical companies, government agencies, and research institutions. These partnerships provide the company with access to expertise, resources, and funding to advance its research and development efforts. Notable collaborations include agreements with the Infectious Disease Research Institute, the National Institute for Innovation in Manufacturing Biopharmaceuticals, and the Brazilian Ministry of Health.
In recent years, Ibio has made significant progress in advancing its pipeline of product candidates. The company has several programs in various stages of development, targeting a range of indications including fibrotic diseases, oncology, and infectious diseases. Notable candidates include IBIO-201, a therapeutic candidate for the treatment of idiopathic pulmonary fibrosis; IBIO-200, a subunit vaccine for COVID-19; and IBIO-400, a next-generation anthrax vaccine.
Ibio has also made strategic acquisitions to further enhance its capabilities and expand its product portfolio. In 2019, the company acquired the technology assets and certain proprietary rights from AzarGen Biotechnologies, a South African company specializing in the development of biopharmaceuticals. This acquisition has strengthened Ibio's position in the global biopharmaceutical market and opened new opportunities for growth.
Overall, Ibio Inc. is a forward-thinking biotechnology company that is leveraging its plant-based expression platform to revolutionize the production of biologics. With a strong pipeline, strategic collaborations, and a track record of successful partnerships, Ibio is well-positioned to make a significant impact in the biopharmaceutical industry.
The core technology of Ibio is its proprietary plant-based expression system, known as the iBioLaunch platform. This platform allows for the rapid and cost-effective production of high-quality proteins, antibodies, and other biologics in plants. By using plants as bioreactors, Ibio is able to bypass many of the limitations and challenges associated with traditional manufacturing methods.
One of the key advantages of the iBioLaunch platform is its scalability. Ibio can quickly scale up production to meet demand, making it an attractive solution for the production of vaccines and other critical medical supplies, especially during times of crisis such as pandemics. This flexibility has positioned Ibio as a leading player in the biotherapeutics market.
In addition to its core platform, Ibio also offers a range of services to support the development and manufacturing of biologics. These services include cell line development, upstream and downstream process development, and analytical testing services. These services enable Ibio to provide end-to-end solutions for its clients, from early-stage development through to commercial manufacturing.
Ibio has a diverse portfolio of collaborations and partnerships with pharmaceutical companies, government agencies, and research institutions. These partnerships provide the company with access to expertise, resources, and funding to advance its research and development efforts. Notable collaborations include agreements with the Infectious Disease Research Institute, the National Institute for Innovation in Manufacturing Biopharmaceuticals, and the Brazilian Ministry of Health.
In recent years, Ibio has made significant progress in advancing its pipeline of product candidates. The company has several programs in various stages of development, targeting a range of indications including fibrotic diseases, oncology, and infectious diseases. Notable candidates include IBIO-201, a therapeutic candidate for the treatment of idiopathic pulmonary fibrosis; IBIO-200, a subunit vaccine for COVID-19; and IBIO-400, a next-generation anthrax vaccine.
Ibio has also made strategic acquisitions to further enhance its capabilities and expand its product portfolio. In 2019, the company acquired the technology assets and certain proprietary rights from AzarGen Biotechnologies, a South African company specializing in the development of biopharmaceuticals. This acquisition has strengthened Ibio's position in the global biopharmaceutical market and opened new opportunities for growth.
Overall, Ibio Inc. is a forward-thinking biotechnology company that is leveraging its plant-based expression platform to revolutionize the production of biologics. With a strong pipeline, strategic collaborations, and a track record of successful partnerships, Ibio is well-positioned to make a significant impact in the biopharmaceutical industry.
iBio, Inc. is a biotechnology company specializing in the development and commercialization of innovative therapeutic solutions, particularly in the fields of biotechnology and biopharmaceuticals. The company utilizes its proprietary platforms and technologies to facilitate the production of plant-based therapeutics and vaccines. Here’s a detailed overview of the segments, products, and services that iBio, Inc. offers:
Segments
1. Therapeutics Development: iBio focuses on developing therapies for various diseases, including cancer and infectious diseases. The company leverages its experience in antibody development to create targeted and effective treatments.
2. Vaccine Development: iBio is heavily involved in the rapid development of vaccine candidates, particularly those derived from its proprietary plant-based expression systems. This includes vaccines targeting seasonal and pandemic influenza, as well as other infectious diseases.
3. Contract Manufacturing: iBio offers contract manufacturing services using its advanced plant-based production capabilities. This segment allows other companies to manufacture their biopharmaceuticals using iBios proven technology.
4. Research and Development Services: The company provides R&D services that include preclinical studies, process development, and scale-up production capabilities.
Products
1. Therapeutic Candidates:
- IBIO-100: A therapeutic candidate targeting fibrosis and related disorders.
- IBIO-200: A therapeutic targeting various cancers through a novel mechanism of action.
- IBIO-300: Designed for the treatment of infectious diseases, employing innovative antibody technologies.
2. Vaccine Candidates:
- IBIO-201: A plant-based vaccine candidate for pandemic influenza.
- IBIO-202: Targets seasonal influenza strains, showcasing the company’s rapid response capabilities.
- COVID-19 Vaccine Development: iBio has been involved in the development of vaccines against COVID-19, utilizing its plant-based technology to create flexible and prompt vaccine solutions.
Services
1. Contract Development and Manufacturing (CDMO):
- iBio offers CDMO services to clients seeking to manufacture protein-based biopharmaceuticals. This includes upstream and downstream processing, formulation, and filling services that are scalable and efficient.
2. Platform Technology Access:
- iBio provides access to its proprietary plant-based expression system, known as the iBioLaunch™ platform. This platform enables partners to develop and produce therapeutic proteins and vaccines quickly and cost-effectively.
3. Consultative Services:
- The company may offer consultative services to leverage their expertise in biopharmaceutical development, from preclinical stages to regulatory advice and market access strategies.
4. Collaborative Research Initiatives:
- iBio often engages in partnerships with academic institutions, government agencies, and commercial entities to foster research initiatives, share knowledge, and co-develop new therapeutic approaches.
Technologies
1. iBioLaunch™ Platform: This is a rapid and flexible plant-based expression technology that allows for the manufacturing of proteins at scale. It provides advantages such as low production costs, high yields, and the ability to quickly adapt to emerging health threats.
2. Monoclonal Antibody Development: iBio employs advanced techniques to create monoclonal antibodies tailored for therapeutic use, particularly in oncology and autoimmune disorders.
3. Plant-Based Production Systems: Utilizing transient expression systems in plants, iBio can produce large quantities of proteins quickly, enhancing the development timelines for vaccines and therapeutics.
Strategic Goals
iBio is focused on leveraging its advanced technologies to become a leader in the biopharmaceutical industry, aiming to offer innovative treatments and quickly respond to emerging health challenges. This is particularly relevant in the context of global public health needs, where rapid vaccine development and manufacturing scalability are crucial.
Overall, iBio, Inc. is positioned at the intersection of biotechnology innovation and public health needs, aiming to provide transformative solutions across a variety of therapeutic and preventive healthcare domains.
Segments
1. Therapeutics Development: iBio focuses on developing therapies for various diseases, including cancer and infectious diseases. The company leverages its experience in antibody development to create targeted and effective treatments.
2. Vaccine Development: iBio is heavily involved in the rapid development of vaccine candidates, particularly those derived from its proprietary plant-based expression systems. This includes vaccines targeting seasonal and pandemic influenza, as well as other infectious diseases.
3. Contract Manufacturing: iBio offers contract manufacturing services using its advanced plant-based production capabilities. This segment allows other companies to manufacture their biopharmaceuticals using iBios proven technology.
4. Research and Development Services: The company provides R&D services that include preclinical studies, process development, and scale-up production capabilities.
Products
1. Therapeutic Candidates:
- IBIO-100: A therapeutic candidate targeting fibrosis and related disorders.
- IBIO-200: A therapeutic targeting various cancers through a novel mechanism of action.
- IBIO-300: Designed for the treatment of infectious diseases, employing innovative antibody technologies.
2. Vaccine Candidates:
- IBIO-201: A plant-based vaccine candidate for pandemic influenza.
- IBIO-202: Targets seasonal influenza strains, showcasing the company’s rapid response capabilities.
- COVID-19 Vaccine Development: iBio has been involved in the development of vaccines against COVID-19, utilizing its plant-based technology to create flexible and prompt vaccine solutions.
Services
1. Contract Development and Manufacturing (CDMO):
- iBio offers CDMO services to clients seeking to manufacture protein-based biopharmaceuticals. This includes upstream and downstream processing, formulation, and filling services that are scalable and efficient.
2. Platform Technology Access:
- iBio provides access to its proprietary plant-based expression system, known as the iBioLaunch™ platform. This platform enables partners to develop and produce therapeutic proteins and vaccines quickly and cost-effectively.
3. Consultative Services:
- The company may offer consultative services to leverage their expertise in biopharmaceutical development, from preclinical stages to regulatory advice and market access strategies.
4. Collaborative Research Initiatives:
- iBio often engages in partnerships with academic institutions, government agencies, and commercial entities to foster research initiatives, share knowledge, and co-develop new therapeutic approaches.
Technologies
1. iBioLaunch™ Platform: This is a rapid and flexible plant-based expression technology that allows for the manufacturing of proteins at scale. It provides advantages such as low production costs, high yields, and the ability to quickly adapt to emerging health threats.
2. Monoclonal Antibody Development: iBio employs advanced techniques to create monoclonal antibodies tailored for therapeutic use, particularly in oncology and autoimmune disorders.
3. Plant-Based Production Systems: Utilizing transient expression systems in plants, iBio can produce large quantities of proteins quickly, enhancing the development timelines for vaccines and therapeutics.
Strategic Goals
iBio is focused on leveraging its advanced technologies to become a leader in the biopharmaceutical industry, aiming to offer innovative treatments and quickly respond to emerging health challenges. This is particularly relevant in the context of global public health needs, where rapid vaccine development and manufacturing scalability are crucial.
Overall, iBio, Inc. is positioned at the intersection of biotechnology innovation and public health needs, aiming to provide transformative solutions across a variety of therapeutic and preventive healthcare domains.